Patients Don't Read Textbooks RA patient unresponsive to biologics, now has enthesitis; what to do? QD Clinics are sponsored by RheumNows Coverage of #ACR23 live from San Diego https://t.co/hlacYXm0Nh https://t.co/52Xy3E8kXi

ACR Reacts to 2024 Medicare Physician Fee Schedule The ACR expressed concern that the conversion factor included in the CMS CY 2024 Medicare Physician Fee Schedule and Quality Payment Program final rule is insufficient to address rising inflation https://t.co/ZkMdqJEOkm https://t.co/70SxSGckGf

Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions. https://t.co/MRFwrCXIlQ https://t.co/Su3nMs4CNW

2023 Medscaped Female Compensation Survey asked What percentage would again chose their specialty ? Top 5 specialties rechosen: Cardiology: 82% & Dermatology: 82% Psychiatry: 81% Allergy and immunology: 80% Neurology: 79% Rheumatology: 78% https://t.co/Zy4AJzb7dn. https://t.co/m9HjQ4T5aW

Long term results of the MAINRITSAN study (Maintenance Remission w/ RTX in Systemic AAV) showed fixed-schedule RTX superior to AZA in preventing major relapses at 84mos (HR 0.38), but tailored-RTX assoc w/ incr risk of major relapse (HR 2.92) https://t.co/xLxvPCsRC9 https://t.co/mWwo7GgCIq

Biologics, #RA and Risk of skin CA (NMSC) is complex. - RA alone is a risk for NMSC 49K study of ABA & NMSC ; - In RCTs, risk same w/ ABA & PBO - Registries & Claims data: equal w/ ABA, csDMARDs. b/tsDMARDs - Pooled obs data shows slight ABA risk https://t.co/tp6F0cJWug https://t.co/u6UdAUZqoc

UK biobank population study shows a bidirectional assoc. betw RA & ILD (each @ incr risk for the other). In non-COPD pts, RA increased risk of COPD (HR=1.65) & in non-RA pts, COPD had a higher risk of future RA (HR=1.67). Both mediated by inflammation https://t.co/imn4ddV7CS https://t.co/UZaszEnCqt

Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/ACe7nDDwop https://t.co/lV66WerkAp

PMR QD Clinics - Teaching Cases https://t.co/fJThsc2T2k https://t.co/c4mAVqfBeO

Late Should Not Be Less Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow . https://t.co/GwJdJKHuDZ https://t.co/S51g7aQ0i4

RheumNow will be providing #ACR23 coverage from Nov 11-15. Tune in for daily recaps, KOL videos, live streaming and more. https://t.co/2kBkHq6rIc

LANCET: Efgartigimod (neonatal Fc receptor mAb) shown effective in chronic #ITP. RCT, 205 pts with refractory ITP (Plt <30K for ~10.6 yrs) Rx w/ EFGR vs PBO. @24 wks EFGR incr Plt >50k in 22% vs. 6%). A larger RCT in progress https://t.co/uXyjYoXlyF https://t.co/jGroGNeD4W